Coagulase-negative staphylococcal bloodstream infections: Does vancomycin remain appropriate empiric therapy?

The Journal of Infection
Paula Valencia-ReyTamar F Barlam

Abstract

It is unknown if vancomycin minimal inhibitory concentrations (MICs) have increased in coagulase-negative staphylococci (CoNS) or whether vancomycin remains appropriate empiric therapy. We performed a retrospective study at a single tertiary care center over 8 years. Adult inpatients with ≥2 positive blood cultures for CoNS within a 48-h period were eligible. Susceptibilities were performed by automated broth based-microdilution. Changes in antimicrobial susceptibility were analyzed using logistic regression. The clinical characteristics and outcomes of patients with bloodstream infections (BSI) were compared by MIC. Of 308 episodes of possible CoNS bacteremia, the vancomycin MIC was ≤1 μg/mL in 80 (26%) isolates, 2 μg/mL in 223 (72.4%) isolates and 4 μg/mL in 5 (1.6%) isolates. No isolates were resistant. We observed an 11-fold increased chance of having an isolate with a vancomycin MIC ≤1 μg/mL in 2009-2011 compared with 2004-2008 (OR 10.8, 95% CI 6.0-19.5, p < 0.05). In 152 patients with BSI, the median days of bacteremia, hospital mortality and readmissions at 30 days were similar in BSI caused by isolates with high vancomycin MICs (2-4 μg/mL) and low vancomycin MICs (≤1 μg/mL). We conclude vancomycin is still appropriate e...Continue Reading

References

Apr 1, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·D O GarrettW R Jarvis
Jul 5, 2002·Clinical Microbiology Reviews·Arjun SrinivasanTrish M Perl
Jun 21, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Muhammad R SohailLarry M Baddour
Dec 14, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J L KutiD P Nicolau
Jan 10, 2008·Journal of General Internal Medicine·Chunliu ZhanClaudia Steiner
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers
Jun 21, 2011·Diagnostic Microbiology and Infectious Disease·Juan J PicazoUNKNOWN VIRA Study Group
Feb 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J van HalD L Paterson
Nov 13, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Geoffrey TsarasElie F Berbari
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Dec 18, 2013·Antimicrobial Agents and Chemotherapy·Larissa MayRamanan Laxminarayan
Jan 31, 2014·Journal of Clinical Microbiology·April M BobenchikRomney M Humphries

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Anucha ApisarnthanarakVictoria J Fraser
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale
Regis G RosaLuciano Z Goldani
© 2022 Meta ULC. All rights reserved